German drugmaker Merck KGaA (MRK: DE) has reported net sales in the 2022 third quarter of 5.8 billion euros ($5.8 billion), in line with many analysts’ expectations, with earnings per share coming in at 2.68 euros.
The performance was driven by strong organic sales growth of 7.1%, and particularly positive earnings developments in the firm’s life science and healthcare divisions.
Merck warned that the impact of inflation was being felt, with persistent increases in the costs of raw materials, energy and logistics weighing on earnings in some parts of the business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze